Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.
Atomoxetine and reboxetine are commonly used as selective norepinephrine reuptake inhibitors (NRIs) for the treatment of attention-deficit/hyperactivity disorder and depression, respectively. Furthermore, recent studies have suggested that NRIs may be useful for the treatment of several other psychiatric disorders. However, the molecular mechanisms underlying the various effects of NRIs have not yet been sufficiently clarified. G-protein-activated inwardly rectifying K(+) (GIRK or Kir3) channels have an important function in regulating neuronal excitability and heart rate, and GIRK channel modulation has been suggested to be a potential treatment for several neuropsychiatric disorders and cardiac arrhythmias. In this study, we investigated the effects of atomoxetine and reboxetine on GIRK channels using the Xenopus oocyte expression assay. In oocytes injected with mRNA for GIRK1/GIRK2, GIRK2, or GIRK1/GIRK4 subunits, extracellular application of atomoxetine or reboxetine reversibly reduced GIRK currents. The inhibitory effects were concentration-dependent, but voltage-independent, and time-independent during each voltage pulse. However, Kir1.1 and Kir2.1 channels were insensitive to atomoxetine and reboxetine. Atomoxetine and reboxetine also inhibited GIRK currents induced by activation of cloned A(1) adenosine receptors or by intracellularly applied GTPgammaS, a nonhydrolyzable GTP analogue. Furthermore, the GIRK currents induced by ethanol were concentration-dependently inhibited by extracellularly applied atomoxetine but not by intracellularly applied atomoxetine. The present results suggest that atomoxetine and reboxetine inhibit brain- and cardiac-type GIRK channels, revealing a novel characteristic of clinically used NRIs. GIRK channel inhibition may contribute to some of the therapeutic effects of NRIs and adverse side effects related to nervous system and heart function.
Kobayashi
Toru
T
Department of Molecular Neuropathology, Brain Research Institute, Niigata University, Chuo-ku, Niigata, Japan. torukoba@bri.niigata-u.ac.jp
Washiyama
Kazuo
K
Ikeda
Kazutaka
K
D018759:Adrenergic Uptake Inhibitors; D000818:Animals; D000069445:Atomoxetine Hydrochloride; D001703:Biophysics; D002492:Central Nervous System Depressants / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004558:Electric Stimulation / Q000379:methods; D000431:Ethanol / Q000494:pharmacology; D005260:Female; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels / Q000235:genetics / Q000378:metabolism*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects* / Q000235:genetics; D008845:Microinjections / Q000379:methods; D009025:Morpholines / Q000494:pharmacology*; D009865:Oocytes; D018408:Patch-Clamp Techniques / Q000379:methods; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics / Q000378:metabolism; D011437:Propylamines / Q000494:pharmacology*; D000077593:Reboxetine; D043682:Receptor, Adenosine A1 / Q000378:metabolism; D014982:Xenopus laevis
D018759:Adrenergic Uptake Inhibitors; D002492:Central Nervous System Depressants; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; C489461:Kir2.1 channel; D009025:Morpholines; D024661:Potassium Channels, Inwardly Rectifying; D011437:Propylamines; D043682:Receptor, Adenosine A1; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D000431:Ethanol; D000069445:Atomoxetine Hydrochloride; D000077593:Reboxetine
Vet Hum Toxicol. 2004 Jun;46(3):130-2
15171487
Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):639-47
16523308
J Biol Chem. 1995 Jan 13;270(2):589-95
7822283
Curr Pharm Des. 2006;12(34):4513-23
17168757
Biol Psychiatry. 2000 May 1;47(9):818-29
10812041
Neurosci Res. 2006 Feb;54(2):104-11
16310876
Br J Pharmacol. 2003 Mar;138(6):1119-28
12684268
J Am Acad Child Adolesc Psychiatry. 2007 Sep;46(9):1119-1127
17712235
Drugs. 2004;64(2):205-22
14717619
Ther Drug Monit. 2001 Feb;23(1):27-34
11206039
Nat Neurosci. 1999 Dec;2(12):1084-90
10570485
Nature. 1993 Aug 26;364(6440):802-6
8355805
J Pharmacol Sci. 2006 Nov;102(3):278-87
17072103
J Neurosci. 1996 Nov 15;16(22):7137-50
8929423
J Emerg Med. 2006 Oct;31(3):267-8
16982359
Int J Clin Pract. 2005 Dec;59(12):1435-40
16351676
Pharmacol Res. 2006 Aug;54(2):136-41
16725344
J Biol Chem. 1995 Dec 1;270(48):28660-7
7499385
Neuron. 1997 Sep;19(3):687-95
9331358
J Clin Psychiatry. 2007 Mar;68(3):390-8
17388708
J Clin Pharmacol. 2002 Nov;42(11):1219-27
12412820
Int J Clin Pharmacol Ther. 2000 May;38(5):254-9
10839469
Circulation. 2004 Sep 7;110(10):1191-6
15337696
Nature. 1993 Mar 4;362(6415):31-8
7680431
Curr Opin Cell Biol. 1999 Aug;11(4):503-8
10449331
Br J Pharmacol. 1989 Sep;98(1):13-28
2679954
J Am Coll Cardiol. 2001 Jun 15;37(8):2136-43
11419900
Cell Signal. 1997 Dec;9(8):551-73
9429760
Biochem Biophys Res Commun. 1995 Mar 28;208(3):1166-73
7702616
Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):923-7
9023358
Neuropsychopharmacology. 2003 May;28(5):932-8
12637950
Br J Pharmacol. 2009 Jan;156(2):226-36
19154426
Dev Med Child Neurol. 2007 Jul;49(7):498-502
17593120
Hum Psychopharmacol. 2005 Apr;20(3):189-92
15799010
Drug Alcohol Depend. 2008 Jul 1;96(1-2):145-54
18403134
Am J Psychiatry. 2004 Apr;161(4):757
15056530
Nucl Med Biol. 2004 Feb;31(2):147-53
15013479
CNS Drug Rev. 2004 Spring;10(1):23-44
14978512
J Neurosci. 2008 Apr 9;28(15):4069-77
18400906
Br J Pharmacol. 2000 Apr;129(8):1716-22
10780978
J Neurosci. 1999 Feb 1;19(3):1006-17
9920664
Nat Rev Drug Discov. 2004 May;3(5):385-6
15152632
Psychopharmacology (Berl). 1994 May;114(4):559-65
7855217
Nature. 1993 Mar 11;362(6416):127-33
7680768
Psychopharmacology (Berl). 2003 Aug;169(1):108-14
12721779
Neuropsychopharmacology. 2006 Apr;31(4):730-8
16052243
Mol Pharmacol. 2002 Jul;62(1):119-26
12065762
Nat Neurosci. 1999 Dec;2(12):1091-7
10570486
J Child Adolesc Psychopharmacol. 2003 Spring;13(1):53-63
12804126
Biochim Biophys Acta. 1999 Oct 15;1421(2):213-33
10518693
J Postgrad Med. 2003 Oct-Dec;49(4):373-5
14699244
Methods Mol Med. 2003;84:53-64
12703317
J Forensic Sci. 2006 Jan;51(1):179-82
16423247
Drug Alcohol Depend. 2008 Apr 1;94(1-3):254-7
18182254
Br J Pharmacol. 2002 Jan;135(2):313-22
11815366
J Pharmacol Exp Ther. 2001 Aug;298(2):521-30
11454913
J Clin Psychiatry. 2002 Jan;63(1):31-7
11838623
Nature. 1995 Mar 9;374(6518):135-41
7877685
J Biol Chem. 2002 Dec 13;277(50):48282-8
12374786
Nucl Med Biol. 2008 Feb;35(2):213-8
18312831
J Neurosci. 1996 Jun 1;16(11):3559-70
8642402
Bioorg Med Chem Lett. 2005 Feb 1;15(3):699-703
15664840